|
66
|
250
|
5l5uA |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
66
|
211
|
5l66K |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with bortezomib |
|
73
|
248
|
5lf7B |
Human 20s proteasome complex with ixazomib at 2.0 angstrom |
|
60
|
222
|
5lttL |
Yeast 20s proteasome with human beta5i (1-138; r57t)in complex with pr-924 |
|
67
|
250
|
5l67A |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with pr-924 |
|
53
|
196
|
5lexJ |
Native human 20s proteasome in mg-acetate at 2.2 angstrom |
|
69
|
244
|
5l5xB |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with onx 0914 |
|
64
|
230
|
5lf1A |
Human 20s proteasome complex with dihydroeponemycin at 2.0 angstrom |
|
65
|
211
|
5l65K |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with carfilzomib |
|
75
|
248
|
5lf4B |
Human 20s proteasome complex with delanzomib at 2.0 angstrom |
|
80
|
245
|
5ls3A |
Crystal structure of metallo-beta-lactamase spm-1 with y58c mutation |
|
58
|
226
|
5l5oH |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
63
|
241
|
5l62G |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
69
|
213
|
5leyL |
Human 20s proteasome complex with oprozomib at 1.9 angstrom |
|
70
|
243
|
5l68F |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
63
|
200
|
5lf3K |
Human 20s proteasome complex with bortezomib at 2.1 angstrom |
|
63
|
231
|
5l67E |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with pr-924 |
|
63
|
211
|
5l5iK |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 9 |
|
64
|
234
|
5lf4E |
Human 20s proteasome complex with delanzomib at 2.0 angstrom |
|
70
|
243
|
5l61F |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
58
|
226
|
5l61H |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
68
|
233
|
5l5xM |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with onx 0914 |
|
57
|
204
|
5m2bI |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor ro19 |
|
57
|
195
|
5l5zJ |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with bortezomib |
|
72
|
230
|
5lchA |
Vim-2 metallo-beta-lactamase in complex with (s)-1-allyl-2-(3-methoxyphenyl)-3-oxoisoindoline-4-carboxylic acid (compound 42) |
|
59
|
196
|
5l5vN |
'yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
67
|
211
|
5l60K |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
66
|
240
|
5m2bC |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with thiazole based inhibitor ro19 |
|
66
|
250
|
5l6cA |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
70
|
244
|
5l61B |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (99-132) in complex with epoxyketone inhibitor 14 |
|
69
|
244
|
5l63B |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
59
|
196
|
5l63N |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
58
|
204
|
5l5pI |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 17 |
|
57
|
204
|
5lttI |
Yeast 20s proteasome with human beta5i (1-138; r57t)in complex with pr-924 |
|
70
|
244
|
5l68B |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
65
|
200
|
5lezK |
Human 20s proteasome complex with oprozomib in mg-acetate at 2.2 angstrom |
|
61
|
195
|
5l5vJ |
'yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
65
|
250
|
5l69A |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 16 |
|
66
|
250
|
5lttA |
Yeast 20s proteasome with human beta5i (1-138; r57t)in complex with pr-924 |
|
67
|
233
|
5l5vM |
'yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
67
|
216
|
5lf7M |
Human 20s proteasome complex with ixazomib at 2.0 angstrom |
|
66
|
233
|
5l68M |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 14 |
|
70
|
243
|
5lttF |
Yeast 20s proteasome with human beta5i (1-138; r57t)in complex with pr-924 |
|
62
|
241
|
5l67G |
Yeast 20s proteasome with mouse beta5i (1-138) and mouse beta6 (97-111; 118-133) in complex with pr-924 |
|
66
|
250
|
5l5vA |
'yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with epoxyketone inhibitor 18 |
|
58
|
196
|
5l60N |
Yeast 20s proteasome with human beta5c (1-138) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
71
|
243
|
5l5sF |
Yeast 20s proteasome with human beta5i (1-138; v31m) and human beta6 (97-111; 118-133) in complex with pr-924 |
|
70
|
240
|
5l55C |
Yeast 20s proteasome in complex with epoxyketone inhibitor 18 |
|
68
|
240
|
5l5qC |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with epoxyketone 18 |
|
62
|
211
|
5l5eK |
Yeast 20s proteasome with human beta5i (1-138) and human beta6 (97-111; 118-133) in complex with carfilzomib |
